Cite this article
Recurrent ovarian clear cell carcinoma: a retrospective evaluation of the efficacy and prognostic factors
1 Department of Gynecology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
Eur. J. Gynaecol. Oncol. 2018 , 39(4), 569–574; https://doi.org/10.12892/ejgo4027.2018
Published: 10 August 2018
Purpose: The aim of this study was to investigate the effectiveness of treatment and prognostic factors in patients with recurrent ovarian clear cell carcinoma. Materials and Methods: The 78 patients with ovarian clear cell carcinoma (CCC) in Peking University Cancer Hospital from 1996 to 2015 received laparotomy and initial chemotherapy. The efficacy of surgery, chemotherapy, and prognosis of patients with recurrent CCC were evaluated. Results: The overall response rate (RR) to platinum based chemotherapy of PTX + platinum regimen showed no significant correlation with PFI in this study (p = 0.683). According to non-platinum regimen, irinotecan + mitomycin C regimen had a higher activity (RR = 41.7%) compared with topotecan regimen (RR = 20%). The overall survival (OS) had a marked correlation with tumor staging (p = 0.027), residuals (p = 0.019), second-line chemotherapy response (p = 0.003), and progression free survival (PFS, p = 0.014). Conclusions: No residual tumor in initial surgery is critical for the prognosis of patients with CCC, even in optimal cytoreductive surgery. Irinotecan, as one kind of effective chemotherapy regimen, is preferred to be conducted in patients with recurrent CCC.
Clear cell carcinoma